|
Scientists working at a Zoetis laboratory. (Photo: Zoetis)
Zoetis to set up aquaculture development vaccine plant in China
(CHINA, 5/3/2018)
Zoetis is to start the construction of state-of-the-art vaccine manufacturing, research and development facilities in Suzhou for pigs, cattle, fish and pets, which help protect them against the prevalent disease strain in China.
Company sources also revealed that in this facility, the company’s PHARMAQ business will begin to develop vaccines for the farmed fish industry in China; the first such R&D centre established by a multinational company to concentrate on aquaculture in mainland China.
Zoetis produces more than 80 product lines that span five product categories, including vaccines, parasiticides, anti-infectives, medicated feed additives and other pharmaceutical products, which serve six core animal species - pigs, dairy cattle, poultry, fish, dogs and cats.
“The future work of our scientists in Suzhou will help accelerate the development of quality vaccines tailored to meet the animal health needs of the China market, and it will enable expansion from our initial focus on vaccines for swine to those for cattle and fish as well as for companion animals,” said Dr. Catherine Knupp, Executive Vice President and President of Research and Development at Zoetis.
“Zoetis scientists from our laboratory in Beijing and our global R&D network will collaborate with the Suzhou-based R&D team, helping speed the introduction of Zoetis technologies and processes into the development of high-quality vaccines and medicines for China,” Knupp added.
At the start-up R&D laboratory in Suzhou, PHARMAQ scientists will primarily concentrate on acquiring in-depth knowledge of the disease threats within the Chinese aquaculture sector.
This know-how will serve as the foundation to develop safe and effective vaccines for the aquaculture industry in China. Vaccines are expected to become an important health management tool for China’s aquaculture industry to help control the diseases that pose the greatest threat to this industry.
China is the world's largest aquaculture nation, producing approximately 50 million metric tonnes of farmed fish in 2016, which represent 63 per cent of global production.
Increased reliance on vaccines to control disease could help reduce use of antibiotics to treat bacterial disease in farmed fish. Once Zoetis completes construction on the new combined R&D and manufacturing facility, R&D operations will transition to the new facility.
“We at Zoetis view China as a global center for high-quality manufacturing as well as innovation,” said Roman Trawicki, Executive Vice President and President of Global Manufacturing and Supply at Zoetis.
“The completion of this new vaccine manufacturing facility in Suzhou will establish a center of excellence for production of quality vaccines tailored specifically to the needs of the Chinese market. It will broaden our manufacturing capacity and capabilities in China,” he stressed.
The new innovation and manufacturing facility in Suzhou will include 43,000 square meters of vaccine manufacturing operations and laboratory space.
Zoetis expects to complete construction and Good Manufacturing Practices certification by the Chinese Ministry of Agriculture by 2021.
editorial@seafood.media
www.seafood.media
Information of the company:
|
Address:
|
100 Campus Drive
|
|
City:
|
Florham Park
|
|
State/ZIP:
|
New Jersey (NJ 07932)
|
|
Country:
|
United States
|
|
Phone:
|
+1 973-8227000
|
|
Fax:
|
+1 302-6555049
|
More about: 
|
|
|
|
Print
